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BACKGROUND: In Brazil, despite the recommendations of the Brazilian Society of Hemodynamics and
Interventional Cardiology, the National Health System has not yet approved the use of drug-eluting stents. In
percutaneous coronary interventions performed in the public and part of the private health care system, bare metal
stents are used as the only option. Therefore, new information on bare metal stents is of great importance. The
primary endpoint was to evaluate the influence of the alloy and the profile of coronary stents on late loss and
restenosis rates 6 months after implantation in patients with multivessel coronary disease.
METHODS: Single center, randomized and prospective study comparison of cobalt–chromium versus stainless steel
stent implantation in 187 patients with multivessel coronary disease. At least one cobalt–chromium and one
stainless steel stent were implanted per patient.
RESULTS: Mean age of patients was 59.5¡10.1 years with a prevalence of males (66.3%) and patients with acute
coronary syndrome (56%). Baseline clinical characteristics were similar with hypertension in 146 (78%), dyslipidemia
in 85 (45.5%) and diabetes in 68 (36.4%). Two hundred and twenty-nine cobalt–chromium and 284 stainless steel
stents were implanted. Angiographic variables showed no statistically significant difference. Angiographic follow-
up to 6 months after implantation showed similar late loss and restenosis rates.
CONCLUSION: The use of two different alloys, stainless steel and cobalt–chrome stents, in the same patient and in
the same vessel produced similar 6-month restenosis and late loss rates.
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Coronary stents; Chromium alloy.
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INTRODUCTION
In Brazil, coronary heart disease is an important cause of
death and hospitalization.1,2 Despite the recommendations of
the Brazilian Society of Hemodynamics and Interventional
Cardiology, a significant percentage of patients are still treated
with bare-metal stents. The National Health System has not yet
incorporated the use of drug-eluting stents (DES).3 Thus, bare-
metal stents are the only option for percutaneous coronary
interventions performed in our public health care system. The
National Agency for Sanitary Surveillance has registered
about 108 bare-metal stents for clinical use; none has fully
met the "optimal stent" criteria.4,5
There is renewed interest in the development of bare-
metal stents because, as these stents improve, so does the
platform for DES. Coronary stents for clinical use are made
from metal alloys, and stainless steel alloy is the most
frequently used. These stents may release heavy metal ions
(nickel, chromium and molybdenum), which can cause
allergic and hypersensitivity reactions resulting in a
stimulus for the proliferation and migration of smooth
muscle cells and consequently restenosis.6
Lately, alloys of nickel–chrome and cobalt–chromium have
been used to improving certain characteristics of stainless
steel stents. Owing to its greater density, this alloy enables the
construction of stents with thinner struts and the same
radiopacity and radial strength as stainless steel with thicker
struts. In turn, the reduced thickness of the struts provides
more flexibility and lower crossing profiles to the stents, thus
reducing the inflammatory response at the implant site and
neointimal thickening, with potentially lower restenosis and
target vessel revascularization rates.7–11
The evidence in experimental studies in animal models
shows that the cobalt–chromium stents with thinner struts
cause less neointimal thickening and percentage of stenosis
compared with the thicker strut stents.8
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Clinical evidence has suggested that patients treated with
thin metal strut stents (,100 mm thick)12 have less
neointimal proliferation and better outcomes than patients
treated with thicker stents.13–15 The first post-implant study
of a cobalt–chromium stent (Multilink Vision registry), with
thick 81-mm struts, showed late loss of 0.83 mm, which is
comparable to the thinnest stainless steel Guidant Multilink
stent with thinner struts (50 mm) and late loss of 0.78 mm.
Restenosis and target lesion revascularization rates were
15.7% and 4.3% respectivelly.16
Unlike stainless steel stents, which have been widely
studied, there are few studies on the efficacy and safety of
cobalt–chromium stents, as the clinical use of these stents
took place in the era of DES.7,8,16–18
The primary endpoint was to evaluate the influence of the
alloy and the profile of coronary stents on late loss and
restenosis rates at 6 months after implantation in patients
with multivessel coronary disease.
METHODS
This is a single center, prospective and randomized trial,
comparing cobalt–chromium stent versus stainless steel
stent implantation in patients with multivessel coronary
disease to evaluate the influence of metal alloys and their
profile on the late loss and restenosis rates 6 months after
implantation in patients with multivessel coronary disease.
The study protocol was approved by the ethics committee of
Instituto de Assisteˆncia Me´dica ao Servidor Pu´blico
Estadual (IAMSPE) and was conducted according to the
principles of the Declaration of Helsinki. All patients gave
written informed consent.
The study included patients with stable angina or acute
coronary syndrome (unstable angina or myocardial infarc-
tion) with de novo multivessel coronary artery lesions of
$70% by quantitative coronary angiographic analysis who
were suitable for stent implantation.
Patients were excluded if there was failure to provide
written informed consent, contraindication to any emer-
gency myocardial revascularization surgery, patients with
single-vessel disease, restenotic lesions, chronic total
occluded lesions, significant left main disease, patients
undergoing primary angioplasty, contraindications to the
use of acetylsalicylic acid or clopidogrel and a left
ventricular ejection fraction of ,30%. Patients with cardio-
genic shock, malignancies or other comorbidities with life
expectancy ,12 months or that may result in non-
compliance with the protocol, or pregnancy were consid-
ered ineligible for the study.
Procedural success was defined as a final reduction in
lumen diameter stenosis of ,20% after stent deployment,
and obtaining TIMI3 flow in the absence of major in-
laboratory and in-hospital complications (death, emergency
bypass surgery, development of a new non-ST elevation
myocardial infarction or ST-elevation myocardial infarction
and target vessel revascularization). ST-elevation myocar-
dial infarction was diagnosed as the development of ST-
elevations on the electrocardiogram and creatine kinase-MB
increase above normal laboratory values. Non-ST-elevation
myocardial infarction was defined as creatine kinase-MB
values three times greater than the normal range with or
without persistent ST-segment or T-wave changes on the
post-procedure electrocardiogram. Major adverse cardiac
events included death, Q-wave myocardial infarction and
any target lesion revascularization. Angiographic restenosis
was defined as stenosis diameter $50% in stent segment or
up to 5 mm proximal and distal to the edge of the stent at
the 6-month angiography. All deaths were considered
cardiac deaths unless clearly documented as non-cardiac
deaths. Angioplasty for subacute stent thrombosis is
considered as target lesion revascularization. Late loss was
defined as a difference between the minimal luminal
diameter immediately after stent implantation and the
minimal luminal diameter at angiographic follow-up. A
control coronary angiography was performed 6 months
after last stent implantation.
Coronary angiography was performed routinely.
Measurements of the interpolated reference diameter, lesion
length and diameter, diameter stenosis and minimal
luminal diameter were obtained before and after the
intervention and at angiography follow-up, from an
angiogram performed after an intracoronary bolus injection
of 20 mg of isosorbide mononitrate in all patients for whom
follow-up angiogram was available. Quantitative coronary
arteriography was performed by an independent radiology
technician at the core laboratories of the Stella Maris
Hospital using the validated automatic edge detection of
Philips System (CAAS II, Pie Medical Imaging, Maastricht,
Netherlands).
Randomization was performed by obtaining a random
sequence of numbers in two columns at www.random.org.
Following the randomization sequence, patients were
divided into two groups (stainless steel stents and cobalt–
chromium stents). After assessing the eligibility of patients
and obtaining informed consent, patients were randomized
according to the sequence for stent implantation (cobalt–
chromium or stainless steel). Implants of at least one
stainless steel stent and a cobalt–chromium stent were
performed per patient in different vessels or in the same
vessel provided there was a distance .10 mm between the
stents. Implantation of both stents was performed in the
same procedure or in another procedure on different dates.
The lesions were treated by standard stenting techniques,
with access through the femoral artery, at the investigator’s
criteria to pre- or post-dilatation. In the case of dissection or
obstructions in proximal or distal areas of the stent, balloon
dilation was carried out. The cobalt–chromium PRO-Kinetic
(Biotronik), the only cobalt–chromium stent available at our
service, and stainless steel stents available at our service
were used. Left ventricular function was expressed as the
global ejection fraction as a percentage, as measured by
angiography before the procedure.
Patients were treated with 200 mg of aspirin daily and
300 mg of clopidogrel on the day before the procedure.
Isosorbide-5 mononitrate (20 mg) was administered intra-
coronarily before the analysis of quantitative coronary
angiography (before and immediately after), and heparin
at a dose of 100 IU/kg was administered intravenously
before implantation. After hospital discharge, 75 mg of
clopidogrel was administered for 30 days and aspirin
indefinitely.
Hospital discharge was schedule for 24–48 hours after
stent implantation if there were no complications.
Patients were evaluated at 6 months post-implant. If the
patient did not come for the scheduled visit, contact was
attempted by various means (telephone, letter, contact your
doctor) to obtain information. In the case of death, telephone
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contact was made with the family and a death certificate
was requested.
During hospitalization and at the 6-month follow-up visit,
the following clinical events were assessed: cardiac death,
myocardial infarction, coronary artery bypass graft (CABG),
any new procedure for percutaneous revascularization (site
of the target lesion or another arterial segment), subacute
coronary occlusion. Creatine kinase and its CK-MB fraction
activity were measured 18 hours after the procedure.
All statistical analyses were performed with Prime.
Results are presented as means ¡ SDs for continuous
variables and as percentages for categorized variables.
Sample size calculation was performed by McNemar’s test,
because these are not independent populations and based
on the assumption of an error of 0.05, with b test power of
0.8 and a rate of target lesion revascularization of 15% for
stainless steel stents and 8% for cobalt–chrome stents.
Differences in continuous variables between groups were
compared by the Student t-test and one-way ANOVA for
comparing more than two groups. Comparison of restenosis
rate by risk factors was performed by Chi-square test, and
late loss was performed by the Kruskal–Wallis test.
RESULTS
Between July 2006 and November 2008, 190 patients with
multivessel coronary disease were selected to receive at
least one cobalt–chromium stent and one stainless steel
stent. There were two deaths from cardiac causes (1.05%)
and one subacute thrombosis (0.5%) successfully treated
with angioplasty in the post-hospitalization follow-up.
These three patients were excluded from analysis, and the
remaining 187 patients were implanted with 229 cobalt–
chromium and 284 stainless steel stents.
The clinical characteristics of the patients are listed in
Table 1. Baseline clinical characteristics were the same as
comparisons were made for the same patient. Mean age was
59.5¡10.1 years with a prevalence of males (66.3%) and
patients with acute coronary syndrome (56%).
Table 2 lists the angiographic variables. No statistically
significant differences were observed between the vessel
diameter, diameter stenosis and lesion length. No statisti-
cally significant differences occurred between late loss and
restenosis 6 months after the implant.
The restenosis rate and late loss were not associated with
gender, hypertension and hypercholesterolemia. However,
they were associated with diabetes (Table 3).
The Pro-Kinetic cobalt–chromium stent and stainless steel
stents available at our service were used in this study
(Table 4). Among the stainless steel stents, there was a
prevalence of thin strut stents (58.1%). When comparing the
rate of restenosis and late loss at 6 months after implanta-
tion between the stainless steel stents with thin or thick
struts and the cobalt chrome stents, there were no
statistically significant differences (Table 5).
In a subanalysis of the sample, 56 patients had two lesions
in one artery (112 lesions), four patients had two lesions in
two arteries (16 lesions) and one patient had two lesions in
three arteries (six lesions), totaling 61 patients (67 arteries,
134 lesions). In these 67 arteries, 67 cobalt–chromium stents
and 67 stainless steel stents were implanted. In 15 arteries
(22.5%), there was restenosis agreement; in 40 arteries
(59.7%), there was agreement on the lack of restenosis and
disagreement in 12 arteries (17.8%), p= 0.8, McNemar’s test
(Table 6). There was no statistically significant difference
between the late loss 6 months after implantation when the
stents were implanted in the same artery (Table 7).
Table 1 - Baseline demographic and clinical
characteristics.
Characteristic (N=187 patients)
Age (years) 59.5¡10.1
Male 124 (66.3%)
Current smoker 71 (37.9%)
Hypertension 146 (78%)
High cholesterol (cholesterol .200 mg/dl) 85 (45.5%)
Family history of coronary disease 116 (62%)
Diabetes (glucose .125 mg/dl) 68 (36.4%)
Prior myocardium infarction 28 (15%)
Prior coronary intervention 33 (17.6%)
Prior CABG 20 (10.7%)
Stable angina 86 (46%)
Unstable angina 30 (16%)
Non ST-elevation myocardial infarction 35 (18.7%)
ST-elevation myocardial infarction 36 (19.3%)
Left ventricular ejection fraction 64.8¡14.6
CABG= coronary artery bypass graft.
Table 2 - Angiographic variables.
Angiographic variables/ stent
Stainless steel
(N=284)
Cobalt–
chromium
(N=229) p*
Reference diameter
Pre 2.93¡0.53 2.85¡0.56 0.10
Post 2.93¡0.53 2.85¡0.32 0.12
6 months 2.89¡0.56 2.83¡0.57 0.06
Minimal luminal diameter
Pre 0.50¡0.32 0.52¡0.31 0.21
Post 2.92¡0.53 2.84¡0.56 0.07
6 months 1.9¡1.14 1.83¡1.1 0.33
Stenosis
Pre 82.08¡10.64 81.39¡10.24 0.22
Post 0.38¡0.51 0.36¡0.84 0.68
6 months 36.63¡35.78 36.43¡34.79 0.42
Extension 14.26¡4.70 13.57¡4.88 0.07
Changes in lumen
Immediate gain (mm) 2.40¡0.55 2.33¡0.59 0.06
Late loss at 6 months (mm) 1.02¡1 1.01¡0.97 0.83
Restenosis rate 96 (33.8%) 74(32.3%) 0.80
*Student-t test.
Table 3 - Comparison of restenosis rate and late loss by
risk factors.
Clinical/angiographic
variable Restenosis (%) p* Late loss (mm) P{
Gender (male versus
female)
32.5 versus
32.3
0.95 1.0¡1.04 versus
0.99¡0.92
0.47
Hypertension versus
normal
33.3 versus
29.6
0.5 0.99¡1.01 versus
0.99¡0.99
0.47
High versus normal
cholesterol
34.9 versus
30.3
0.29 1.03¡1.0 versus
0.97¡1.01
0.59
Diabetes versus
normal
39.9 versus
28.1
0.006 1.16¡1.03 versus
0.91¡0.98
0.01
*Chi-square test.
{Kruskal–Wallis test.
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DISCUSSION
This prospective study with a randomized sequence
of stent implantation, comparing the Pro-Kinetic cobalt–
chromium stent and stainless steel stents, showed no
statistically significant difference in restenosis and late loss
rates at 6 months post-implantation between the two
groups.
The strength of this study is that the comparison between
the two stents was performed in the same patient and, in
about one third of patients, the implant was performed in
the same artery, matching not only the biological factors but,
in most patients, the angiographic variables as well.
Therefore, the result was influenced solely by the type of
stent. Another advantage in comparing the implantation of
two types of stents in the same patient is the smaller sample
required to achieve significance.19
In-stent late loss assessed by quantitative coronary
angiography is the measure that best reflects the real and
pure biological effect of the performance of coronary
stents.20 In the current study, which used the same clinical
variables and where the angiographic variables showed no
statistically significant difference, it was observed that late
loss was similar for both stents, whether implanted in
different vessels or in the same vessel.
The cobalt–chromium stent and most stainless steel stents
(58.1%) used in this study are considered to be thin strut
stents (100 mm). Clinical evidence has suggested that
patients treated with thin strut stents (,100 mm thick) show
less neointimal proliferation and better outcomes than
patients treated with stents with thicker struts. In the
national registry, Salles et al. (2008)21 assessed the rate of
target vessel revascularization, hospital stay and mean 18-
month patient follow-up with the contemporary thin strut
cobalt–chromium stents (Driver, Medtronic, United States -
World Headquaters, 710 Medtronic Parkway, Minneapolis,
MN 55432-5604) and stainless steel (Liberte´, Boston
Scientific) stents and observed no significant statistically
differences between them.
Randomized quantitative coronary angiographic studies
comparing stents with the same configuration and different
thicknesses (Multi-Link versus Multi-Link Duet with struts
of 50 mm and 140 mm respectively)13 and stents with
different configurations and different strut thicknesses
(Multi-Link versus BX Velocity and Multi-Link versus
GFX)14,15 showed a lower restenosis rate when the thinnest
stent struts were used. In this study, stainless steel and
cobalt–chromium stents showed similar restenosis rates,
although not all stainless steel stents had thin struts (41.9%),
which should have a negative impact.
A recent randomized trial comparing the rate of target
lesion revascularization and percentage diameter stenosis at
9 months after implantation of stainless steel stents (Taxus
Express, struts 96 mm thick) and platinum chromium (Taxus
Element, struts 81 mm thick), both paclitaxel-eluting stents,
showed no differences in the results, which reinforces the
outcomes of the present study.22
In this study, there was restenosis agreement in 15 arteries
(22.5%), agreement of no restenosis in 40 arteries (59.7%) and
disagreement in 12 arteries (17.8%). These findings indicate
that there are populations of patients that are likely to
develop coronary restenosis and that the rates of angio-
graphic restenosis (including late luminal loss) showed a
bimodal, non-Gaussian distribution.23–25 Diabetes was the
only clinical variable correlated with higher probability of
development of restenosis and higher late loss.
The clinical implications of this study are the compat-
ibility of the use of stainless steel and cobalt–chromium
stents in the same patient and in the same vessel, and
possibly that restenosis depends largely on the patient’s
predisposition to develop it.
One limitation of this study was the use of different types
of stainless steel stents of different sizes, which may have
influenced the results. Another limitation was the non-
performance of intracoronary ultrasound to assess athero-
sclerotic plaques, as it included patients with stable angina
and patients with acute coronary syndrome, which could
influence the results.
Table 4 - Type of stent.
Type of stent Number (%) Strut thickness (mm)
Stainless steel stent 284
Traveller 89 (31.3) 130
Flexmaster 57 (20.1) 90
Biodivysio 39 (13.7) 96
Apolo 31 (10.9) 91
R Stent 22 (7.8) 130
Matrix 18 (6.3) 83
Helistent 9 (3.2) 92
Chopin 8 (2.8) 130
Lekton 8 (2.8) 80
Liberte´ 3 (1.1) 96
Cobalt–chromium stent
Pro-Kinetic 229 80
Table 5 - Restenosis and late loss rates.
Stent Restenosis (%) Late loss (mm)
Cobalt–chromium 74 (32.3) 1¡0.96
Stainless steel (thin struts) 62 (33.2) 0.99¡1.03
Stainless steel (thick struts) 34 (35.1) 1.02¡0.96
p (one-way ANOVA) 0.89 0.97
Table 6 - Agreement of stent restenosis in the same
artery.
Restenosis
Stainless steel
No restenosis
Stainless steel Total
Restenosis Cobalt–
chromium
15 6 21
No restenosis
Cobalt–chromium
6 40 46
Total 21 46 67
p=0.77 (McNemar’s test).
Table 7 - Late loss for stainless steel and cobalt–chromium
stents in the same artery.
Stent
Vessel
diameter
Lesion
extension
6-month late loss
(N =67)
Stainless steel (mm) 2.99¡0.54 14.10¡4.64 1.06¡1.07
Cobalt–chromium (mm) 2.99¡0.58 13.75¡4.94 1.01¡1
p (Student t-test) 1 0.07 0.63
Influence of alloy and coronary stent profile
Abreu LM et al.
CLINICS 2011;66(6):985-989
988
CONCLUSION
Comparison of stents made from two different alloys,
stainless steel and cobalt–chrome stents, in the same patient
and in the same vessel showed similar 6-month restenosis
and late loss rates.
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